YD Bio Limited Ordinary Shares
HealthcareNASDAQ:YDES · NASDAQ Global Select
+$0.02 today
Vol 0.01M · Avg 0.02M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$8.3M -488.8% | -$1.4M -10509.7% | $13.6K -99.6% | $3.8M -56.5% | $8.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $209.6K +100.1% | $104.7K +4171.4% | $2.5K | $0 | $0 | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$1.5K -105.5% | $26.6K +549.8% | $4.1K | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.7M -196.9% | -$567.8K -348.2% | -$126.7K +81.8% | -$697.5K -210.3% | $632.2K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$358.9K -3157.2% | -$11.0K +82.7% | -$63.9K | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | -$1.8M -6560.0% | $28.5K +193.3% | -$30.6K | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $386.4K +3690.0% | $10.2K +89.1% | $5.4K +101.0% | -$530.9K -200.0% | $531.2K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $129.1K +121.7% | -$595.5K -1481.3% | -$37.7K +77.4% | -$166.5K -264.9% | $101.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $3.2M +28304.3% | $11.2K -77.9% | $50.9K +100.8% | -$6.1M +39.0% | -$10.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$6.6M -259.1% | -$1.8M -3200.2% | -$55.7K +98.2% | -$3.0M -339.1% | -$688.4K | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.4M +50.5% | -$2.9M -1003691.0% | -$290 | $0 +100.0% | -$5 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 +100.0% | -$528.5K +62.3% | -$1.4M -21.8% | -$1.1M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $10.3K | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 +100.0% | -$2.8M -636.6% | $528.5K -99.5% | $101.8M | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$1.4M +50.4% | -$2.9M -1000131.0% | -$290 -100.0% | $100.4M +8828.4% | -$1.1M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$33.0K -1.1% | -$32.6K -100.8% | $4.2M +265.3% | $1.1M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $10.7M +36.1% | $7.9M +14744.0% | $53.0K | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 +100.0% | -$101.5M | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $173.5K +274.3% | -$99.6K -206.4% | $93.5K | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $10.9M +40.7% | $7.7M +6685.4% | $113.9K +100.1% | -$97.3M -8564.8% | $1.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $42.9K -22.1% | $55.0K +5693.7% | -$984 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $2.9M -5.6% | $3.0M +5246.6% | $57.0K +552.7% | $8.7K +101.3% | -$688.4K | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$8.0M -69.3% | -$4.7M -8386.3% | -$55.9K +98.1% | -$3.0M -339.1% | -$688.4K | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
BlackRock Technology and Private Equity Term Trust
BTX
$1.05B
Theravance Biopharma, Inc.
NASDAQ:TBPH
$857.84M
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
SEC Filings
Recent regulatory filings
No filings found.
Does YDES generate free cash flow?
YD Bio Limited Ordinary Shares (YDES) generated -$8,036,720.00 of free cash flow in fiscal 2025.
How much operating cash flow does YDES produce?
Operating cash flow was -$6,596,706.00, before capital expenditures of $1.44M.
Explore More
Continue the stock analysis
Jump to another research area for this company.